← Ocular Therapeutix, Inc. (OCUL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ocular Therapeutix, Inc. (OCUL)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
13
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Ocular Therapeutix (OCUL) is a specialty ophthalmic biopharmaceutical company with 274 employees and a $2.1B market cap, built around sustained-release drug-delivery platforms for the eye. The company has a deep pipeline spanning post-surgical inflammation, glaucoma, wet AMD, diabetic retinopathy, and dry eye, with several Phase 3 programs approaching key readouts in 2027. It is pre-profitability, burning roughly $266M net in 2025, but holds $667M in cash—approximately 30 months of runway.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 3 · Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24imp 9/10
- 2027-06-12 (est.)PDUFA · Axpaxliimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OTX-TKI (axitinib implant) | Phase 3 | Neovascular Age-Related Macular Degeneration |
| OTX-TP | Phase 2 | Glaucoma |
| Punctum Plug | Phase 3 | Post Ocular Surgical Inflammation and Pain |
| OTX-CSI | Phase 2 | Dry Eye Disease |
| OTX-DED | Phase 2 | Dry Eye |
| Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy |
| Ophthalmic Insert | Phase 3 | Open Angle Glaucoma and Ocular Hypertension |
| OTX-TIC low dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma |
| Dextenza Ophthalmic Insert | Phase 3 | Cataract |
| Travoprost | Phase 3 | Open Angle Glaucoma |
| OTX-DP (Dexamethasone punctum plug) | Phase 2 | Ocular Inflammation and Pain |
| Dexamethasone, 0.4mg | Phase 3 | Allergic Conjunctivitis |
| Controlled Insertion | Phase 2 | Dry Eye Syndromes |
Price & technical context
3-month
-24.4%
6-month
-12.5%
12-month
-34.0%
52-wk range
$6.88–$16.11
vs 50-day MA
-25.6%
vs 200-day MA
-24.6%
Realized vol
73.6%
Max drawdown
-57.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OCUL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.